Patents Assigned to IRM LLC
  • Heterotetracyclic compounds as TPO mimetics
    Patent number: 8153671
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: April 10, 2012
    Assignee: IRM LLC
    Inventors: Phillip B. Alper, Thomas Marsilje, Arnab Chatterjee, Wenshuo Lu, Daniel Mutnick, Michael Roberts, Yun He
  • COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS
    Publication number: 20120065184
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.
    Type: Application
    Filed: September 8, 2011
    Publication date: March 15, 2012
    Applicant: IRM LLC
    Inventors: Yi Fan, Jon Loren, Valentina Molteni, Pamela A. Albaugh, Gregory Chopiuk, Jeffrey M. Smith, Brenton T. Flatt
  • METHODS AND COMPOSITIONS FOR TREATING ALLERGIC DISEASES
    Publication number: 20120027756
    Abstract: Disclosed in the present invention are antibodies that specifically recognize and antagonize human TSLP receptor, and methods of employing these antibodies to treat or ameliorate diseases or disorder mediated by TSLP signaling.
    Type: Application
    Filed: September 23, 2011
    Publication date: February 2, 2012
    Applicant: IRM LLC
    Inventors: Liqun DONG, Marc NASOFF
  • Compositions and methods for modulating c-kit and PDGFR receptors
    Patent number: 8106068
    Abstract: The invention provides compounds of Formula (2), and pharmaceutical compositions thereof, wherein R1, R2, R3, R4 and L are as described herein; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR?, PDGFR?, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF?, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2?, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: January 31, 2012
    Assignee: IRM LLC
    Inventors: Zuosheng Liu, Jon Loren, Valentina Molteni, Juliet Nabakka
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8101608
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-II, Rsk1, SGK, TrkA, TrkB and TrkC kinases.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: January 24, 2012
    Assignee: IRM LLC, a Delware Limited Corporation
    Inventors: Yongqin Wan, Yuan Mi, Yi Fan, Dai Cheng, Yi Liu, Nathanael S. Gray, Pamela Albaugh
  • Methods and compositions for treating allergic diseases
    Patent number: 8097705
    Abstract: Disclosed in the present invention are antibodies that specifically recognize and antagonize human TSLP receptor, and methods of employing these antibodies to treat or ameliorate diseases or disorder mediated by TSLP signaling.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: January 17, 2012
    Assignee: IRM LLC
    Inventors: Liqun Dong, Marc Nasoff
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20110306625
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
    Type: Application
    Filed: August 27, 2010
    Publication date: December 15, 2011
    Applicants: NOVARTIS AG, IRM LLC
    Inventors: Shenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
  • COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS
    Publication number: 20110263610
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).
    Type: Application
    Filed: March 30, 2009
    Publication date: October 27, 2011
    Applicant: IRM LLC
    Inventors: Yongqin Wan, Shifeng Pan, Guobao Zhang, Xia Wang, Yun Feng Xie, Jiqing Jiang, Dean Phillips, Yang Yang
  • COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
    Publication number: 20110263557
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119; such as, but not limited to, diabetes, obesity and associated metabolic disorders. Formula (I) is a compound, in which A can have up to 2 ring —CH2- group substituted with —C(O)— and can be partially unsaturated with up to 2 double bonds; Wi and W2 are independently selected from CR10 and N; wherein R10 is selected from hydrogen and C1_6alkyl; Yi is selected from NRn, O and S; wherein Rn is selected from hydrogen and C1_6alkyl; Y2 and Y3 are independently selected from CH and N; Y4 is selected from CH2, OCH2 and NR15; wherein R15 is selected from hydrogen and C1_6alkyl; or the pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: April 3, 2009
    Publication date: October 27, 2011
    Applicant: IRM LLC
    Inventors: Christopher Cow, Robert Epple
  • COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS
    Publication number: 20110257077
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.
    Type: Application
    Filed: April 19, 2011
    Publication date: October 20, 2011
    Applicant: IRM LLC
    Inventors: David C. Tully, Amab K. Chatterjee, Agnes Vidal, Hank Michael James Petrassi, Zhiwei Wang, Badry Bursulaya, Glen Spraggon
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20110257154
    Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
    Type: Application
    Filed: June 29, 2011
    Publication date: October 20, 2011
    Applicant: IRM LLC
    Inventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, Wenshuo Lu, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20110257155
    Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
    Type: Application
    Filed: June 29, 2011
    Publication date: October 20, 2011
    Applicant: IRM LLC
    Inventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, Bei Chen, Tetsuo Uno
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8039479
    Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: October 18, 2011
    Assignee: IRM LLC
    Inventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, Bei Chen, Tetsuo Uno
  • COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
    Publication number: 20110245220
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Application
    Filed: October 1, 2010
    Publication date: October 6, 2011
    Applicant: IRM LLC
    Inventors: Mihai Azimioara, Christopher Cow, Robert Epple, Gerald Lelais, John Mecom, Victor Nikulin
  • N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS
    Publication number: 20110237573
    Abstract: The present invention relates to compounds of formulae 1 and 2 and methods for modulating the Wnt signaling pathway using these compounds, wherein A1, A2, B, Y and Z all represent rings.
    Type: Application
    Filed: March 1, 2010
    Publication date: September 29, 2011
    Applicant: IRM LLC
    Inventors: Dai Cheng, Guobao Zhang, Dong Han, Wenqi Gao, Shifeng Pan
  • COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
    Publication number: 20110190263
    Abstract: The invention provides compounds of Formula (I): pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Application
    Filed: February 20, 2009
    Publication date: August 4, 2011
    Applicant: IRM LLC
    Inventors: Mihai Azimioara, Christopher Cow, Robert Epple, Songchun Jiang, Gerald Lelais, Baogen Wu, Daniel Mutnick
  • COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
    Publication number: 20110190264
    Abstract: The invention relates to triazine and pyrimidine derivatives having Formula (1) or (2), and methods for using such compounds. For example, the compounds of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like growth factor (IGF-IR), and/or insulin receptor (InsR) or a combination thereof.
    Type: Application
    Filed: April 3, 2009
    Publication date: August 4, 2011
    Applicant: IRM LLC
    Inventors: Tao Jiang, Pierre-Yves Michellys, Truc Ngoc Nguyen, Wei Pei, Baogen Wu, Xuefeng Zhu
  • 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY
    Publication number: 20110190298
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent; diseases or disorders associated with the activity of GPR119.
    Type: Application
    Filed: July 9, 2009
    Publication date: August 4, 2011
    Applicant: IRM LLC
    Inventors: Robert Epple, Gerald Lelais, Victor Nikulin
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20110190259
    Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
    Type: Application
    Filed: March 15, 2011
    Publication date: August 4, 2011
    Applicant: IRM LLC
    Inventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
  • HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS
    Publication number: 20110183997
    Abstract: The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFR? and PDGFR? kinases.
    Type: Application
    Filed: February 20, 2009
    Publication date: July 28, 2011
    Applicant: IRM LLC
    Inventors: Donatella Chianelli, Xiaolin LI, Xiaodong Liu, Jon Loren, Valentina Molteni, Juliet Nabakka, Vince Yeh